Aaram Omar Kader talks about the PENELOPE study, that investigated the effect of a guideline-based approach on achieving LDL-c goals in very high-risk ACS patients in the Netherlands.
CSI Barcelona To their disappointment, Biljana Parapid and Milena Jancev still have to discuss the topic of underrepresentation of women in clinical research. What are solutions to this problem?
CSI Barcelona What is CODE-EHR and why has this framework been developed? Prof. Asselbergs gives a brief overview in response to questions of Joris Holtrop.
CSI Barcelona What is the risk of CVD in patients with autoimmune diseases and has this yet been incorporated in the guidelines? Marga Helmink interviews Prof. Sattar on this topic.
CSI Barcelona In response to the Grand Debate "Time to say goodbye to aspirin in CVD prevention?" at the ESC 2022, Katrien Castelijns asks Prof. Cleland about his view on this topic.
ESC 2022 In a subpopulation of patients with rheumatic heart disease and AF, the effect of rivaroxaban vs. VKA was examined for the composite outcome of stroke, systemic embolism, MI and death from vascular or unknown cause.
ESC 2022 Otavio Berwanger talks about the win-ratio analysis of the PARADISE-MI trial, a randomized, double blind trial with sacubitril/valsartan vs. ramipril in patients with acute MI.
ESC 2022 ‘There is a lot of misinformation about how dangerous statins are’ says Prof. Baigent. This analysis showed that there is a small excess of muscle symptoms in the first year after starting statin therapy, but no excess in risk thereafter.
ESC 2022 An analysis of the REDUCE-IT trial showed that use of icosapent ethyl reduces the rate of MI overall, and of MI subtypes including STEMI, NSTEMI, MI leading to cardiac arrest and resuscitated MI, when compared to placebo.
ESC 2022 In the phase 2 AXIOMATIC-SSP trial, five doses of the FXIa inhibitor milvexian were examined for secondary prevention in patients with previous ischemic stroke or TIA.
ESC 2022 A randomized study showed that initial echocardiogram assessment of LVEF by AI was noninferior and superior to initial sonographer assessment.
ESC 2022 To answer the question which drug - aspirin or P2Y12i monotherapy - is preferable in patients with CAD, a meta-analysis of seven trials with individual level data was undertaken.